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Mental Health Disorders including schizophrenia, bipolar and schizoaffective 
disorders are often treated using psychotropic medications with evidence that some 
of these medications such as antipsychotics could be associated with significant oral 
side-effects. In this comprehensive review, we examine the psychotropic 
medications mechanisms of action and their oral side-effects, with specific focus on 
psychotropic medications and bruxism as a major oral health complication with a 
negative impact on the quality of life of mental health sufferers, relevant to 
psychiatrists, dentists and general practitioners. Bruxism could be caused by the 
antipsychotics extrapyramidal side-effects through dopaminergic receptors. Bruxism 
as a side-effect of psychotropic medications could result in significant consequences 
to oral health such as tooth structure destruction and irreversible harm to the 
temporomandibular joint. The review findings could assist in understanding the 
aetiology of bruxism, establish appropriate management plan, while supporting 








Mental health conditions such as depression and psychosis are prevalent ranging 
from15-25% of the population 1.  Hence, a significant proportion of dental patients 
could suffer from co-morbid mental health diseases and the dentists may be their 
first point of contact in community and hospital settings. Patients suffering from 
mental health conditions have a higher risk of poor oral hygiene 2, which is increased 
with the chronic use of antipsychotics, antidepressants and mood stabilizers 3. 
Several oral conditions such as bruxism could be due to the mental health condition 
or a result of the psychotropic medications adverse-effects with evidence that 
schizophrenia patients are more vulnerable to the development of 
Temporomandibular dysfunction (TMD) signs such as bruxism 4, while there is a 
clear relation between Selective Serotonin Reuptake Inhibitors (SSRI) use and the 
risk of bruxism 5, 6 and nocturnal bruxism has been reported with venlafaxine 7.  
TMD is described as pain and dysfunction of the masticatory musculature and/or the 
temporomandibular joint (TMJ) (joints connecting the mandible to the skull) and 
associated structures with no clear single aetiology with suggested multifactorial 
aetiologies including anatomical, neuromuscular, psychological, trauma and general 
diseases 8. Patients suffering with TMJ problems may present with pain, limited 
range of jaw motion, clicking noises, dislocation with occlusal changes; deviation of 
the jaw to the side, forward protrusion of the mandible, difficulty swallowing, mouth 
drooling, difficulty chewing and articulating 9. These clinical symptoms may also be 
associated with tooth wear and functional habits. TMJ dislocation is usually 
unilateral, although reports showed that the mechanical energy derived from 
oromandibular dystonia could cause bilateral dislocations.  
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Bruxism is a common problem with worldwide prevalence 5% to 40% 10. This 
prevalence is high in children and adolescents with mental health conditions 
(~30.0%) 11  or developmental disabilities (25% to 69%) 12-14. Bruxism is a motor 
disorder 15 involving a repetitive jaw-muscle activity, an involuntary act of clenching 
or grinding one’s teeth, either while awake or asleep, in an occasional to constant 
manner 16.  Sleep bruxism, which is more common, is characterized by a rhythmic 
activity of the temporomandibular muscles causing a forced contact between dental 
surfaces; accompanied by tooth clenching or grinding with anxiety and stress as 
established risk factors 17. Bruxism has been implicated in tooth wear 18, where tooth 
attrition (a gradual loss of hard tooth substance from occlusal contacts with an 
opposing dentition or restoration) may be accelerated by parafunctional habits of 
bruxism 19. Bruxism could lead to jaw-muscle hypertrophy; fracture or failure of teeth 
restorations or implants 20.  The International Classification of Sleep Disorders 
suggests the following criteria for sleep bruxism: (I) the presence of teeth grinding 
during sleep; and (II) at least one associated feature: abnormal tooth wear, muscular 
discomfort, or sound associated with the tooth grinding 21. 
Methods 
In this review, we searched the published literature on the association between 
antipsychotics and bruxism (National Library of Medicine’s PubMed and PsycINFO 
databases) for published articles between January 1980 and February 2017 using 
keywords “oral diseases,” “bruxism” in association with one of the following: 
“antipsychotics”, “stimulants”; “dopaminergic” “Psychotropic medications “, to identify 
the research papers describing the link between antipsychotics and bruxism. 
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Furthermore, a search using the term bruxism was carried out on the weekly journal 
Reactions, which deals with the side effects of drugs and the VigiAccess database 
through Uppsala monitoring centre for drug side effects to detect relevant information 
regarding the association between bruxism and dopamine-related medications. 
Pharmacology of Psychotropic Medications and Bruxism Aetiology 
Neuropharmacological studies in animals described the striatum as the brain 
structure involved in gnawing/biting behaviour  22 and suggested oral motor activities 
could be influenced by dopamine (DA) antagonists 23, while D2 receptors functional 
neuroimaging in sleep bruxing individuals showed a possible central dopaminergic 
system role in the pathophysiology of sleep bruxism 24. Urinary levels of 
catecholamines, specifically adrenaline, noradrenaline and dopamine, in subjects 
with bruxism were higher compared to control individuals 25. The mechanism of 
bruxism is not fully understood. It could be due to peripheral morphological 
alterations such as malocclusion 26, 27 or multifactorial aetiology including 
psychological, physiological factors 27 with the possibility as a centrally mediated 
condition, modulated by drugs acting on CNS neurotransmitters.  
DA is a catecholamine neurotransmitter and a precursor for norepinephrine and 
epinephrine. Catecholamines affect complex processes such as mood and 
attentiveness and their pathways arise from small clusters of neurons with widely 
divergent projections 28. DA receptors are G-protein coupled receptors, where 
activation of D1 class (D1 and D5) leads to increased cAMP, while D2 class (D2, D3, 
and D4) activation inhibits cAMP generation. These receptors are expressed in the 
brain, where they play a role in motor control, prolactin secretion and motivation and 
affect regulation 28. DA is the therapeutic target in several CNS disorders, including 
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Parkinson’s disease (PD) and schizophrenia; schizophrenia is in part caused by 
dysregulated DA neurotransmission in the brain as shown by PET scans 28, while 
amphetamines and cocaine increase DA levels and/or activate DA receptors leading 
to a schizophrenia-like state 28.  
Antipsychotics long-term use, especially first generation, may cause extrapyramidal 
side-effects (dystonia/dyskinesia) due to DA receptor blockade in the basal ganglia 
leading to slowness, stiffness, tremor, tardive dyskinesia 29; involuntary hyperkinetic 
motor disorders affecting the orofacial region such as bruxism 30. Oral dyskinesia 
could cause TMJ degenerative changes, mucosal lesions, damage to teeth and 
dental prostheses, while oromandibular dystonia produces involuntary and excessive 
contractions of tongue, lip and jaw muscles 31. Second generation antipsychotics 
(SGA) such as clozapine, olanzapine and quetiapine could ameliorate the negative 
symptoms of schizophrenia and have a relatively low affinity for D2 receptors with 
effects on oral health, although to a lower extent. Other dental complications 
associated with psychotropic medications include xerostomia 32 and rabbit syndrome 
33. Risperidone was more associated with tardive dyskinesia compared to clozapine, 
olanzapine and quetiapine 34.  SGA have a high incidence of metabolic dysfunction, 
weight gain; when associated with poor oral hygiene, may cause other oral diseases 
such as dental caries 35.  
Stimulants such as amphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), 
and cocaine exert their effects by enhancing norepinephrine and/or dopamine 36. 
Amphetamines oral health complications 37 include broken or missing teeth, bruxism, 
xerostomia 38 and increased risk of gingival enlargement 39. Ecstasy is also 
associated with bruxism, periodontitis and xerostomia 40, 41.  
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Bruxism and Antipsychotics Medications 
Several clinical studies showed higher TMD signs among psychiatric patients 
especially those suffering from schizophrenia 2, 3, 42. Factors associated with bruxism 
studied in 389 children with developmental disabilities showed that individuals with 
reported involuntary movements had a greater chance of exhibiting bruxism with an 
increased risk with psychotropic drugs use 43. In 339 institutionalized patients 
compared to matched-control subjects, the prevalence of TMD signs, severe tooth 
wear and bruxism were significantly higher 42.  Abnormal attrition was evident in 
46.8% of the psychiatric patients compared with just 20% in the control group with 
significant differences in mean muscle sensitivity to palpation, joint sensitivity to 
palpation and range of mouth opening 3. Abnormal attrition involves both enamel and 
dentin with extensive hard tissue loss that cannot be easily restored. A case report 
described the successful management of antipsychotic induced bruxism upon 
switching to clozapine; while another report presented two cases of acute bruxism 
and akathisia, as early side-effects of antipsychotics, which were relieved by adding 
propranolol 23. Eight cases of bruxism following long-term treatment with haloperidol 
were described 44.  
Pain Perception in Schizophrenia  
As there are few controlled studies, there is a debate regarding sensation threshold, 
pain threshold, and pain tolerance 45, 46. Patients suffering from psychotic disorders 
may not be reliable in reporting the pain due to their psychiatric disorder as 
schizophrenia could cause impairment in communication and social skills, while 
psychotropics may affect pain perception. Several psychiatric reports confirmed the 
insensitivity to pain with possible affective and sensory abnormalities 47-50. For 
schizophrenia patients, behavioural pain activity and self-reported responses to pain 
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are reduced 51. This could lead to delays in diagnosis and treatment, for example 
long-term bruxism may cause the transition of pain from an acute to a chronic phase, 
causing disability and psychologic distress 52.  
Bruxism in patients on Psychostimulants  
Psychostimulants may seriously damage the oral environment and cause bruxism by 
deregulating the DA mesocortical pathway. Methylphenidate, commonly used in the 
treatment of attention-deficit hyperactivity disorder (ADHD), could induce sleep 
bruxism 53 as highlighted in a case report of 2 ADHD children who developed 
dyskinesia and bruxism 54. Long-term drug abuse led to a high prevalence of oral 
motor behaviour, and signs/symptoms of TMD 55. Amphetamine users displayed 
typical, continuous chewing or tooth-grinding movements and bruxism 37, 56, 57 and a 
large cohort study confirmed methamphetamine association with bruxism 37. A case 
study reported three patients suffering from awake bruxism after chronic MDMA 
consumption 58 and a study on the subjective experience/psychologic and behaviour 
sequel of the intake of MDMA, 30% of the patients reported bruxism as an adverse 
effect 59. Among cocaine users, severe bruxism symptoms were reported 60 and 
several reports confirmed the detrimental effects of cocaine misuse on oral health 61, 
62. Repeated stimulation of the dopaminergic systems with apomorphine and cocaine 
increased non-functional masticatory movements and mandibular incisors attrition 
rate in rats 63.  
Discussion 
Oral health is of primary importance for patients suffering with mental disorders as it 
can influence social interactions and exacerbate psychosocial aspects. TMD 
involves the masticatory musculature and/or the temporomandibular joint and 
associated structures and are often associated with pain and/or parafunctional 
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activities, such as bruxism with the long term use of psychotropic medications acting 
as a possible culprit 3. A meta-analysis showed that anti-depressants such as 
duloxetine, paroxetine and venlafaxine were associated with sleep bruxism, 
however, no clear association between valproate, carbamazepine or 
benzodiazepines with bruxism found (low overall quality of evidence) 64. 
Schizophrenia is a severe and debilitating condition that influences an individual’s 
quality of life especially by lack of perception of general and oral health. Patients 
suffering from schizophrenia could present with only a small number of remaining 
teeth, non-functional teeth with excessive mobility; advanced stages of periodontitis. 
They are more prone to the TMD signs and severe tooth wear 42 due to the 
psychotropic medications antagonist activity on the DA receptors 65. Furthermore, 
some typical antipsychotics have strong anticholinergic activities similar to tricyclic 
anti-depressants, with further detrimental effects on oral hygiene such as reduced 
saliva secretion resulting in dry mouth with occasional swallowing difficulties, 
increased risk of caries, gingivitis, periodontitis and candidiasis 66.  
A search carried on the weekly journal Reactions, which deals with medications side 
effects and VigiAccess database (Table 1 and Figure 2) confirmed bruxism as an 
oral side-effect associated with psychostimulants and antipsychotics including 
chlorpromazine, trifluoperazine, haloperidol and aripiprazole. There were 58 hits for 
Bruxism as an oral side effect in Reactions, however, there are limitations regarding 
the available information on number of individuals exposed to each drug and the 
likely risk of polypharmacy.  
The available evidence suggests a relation between tooth wear, psychiatric disorders 
and administration of certain drugs. Poor oral hygiene and extensive unmet needs 
for dental treatment can be significant among psychiatric patients with increased 
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incidence of TMJ disorders due to the psychiatric illness or the psychotropic 
medications side-effects, as well as lifestyle differences. The risk of bruxism is higher 
in special populations such as children and older people. More research is needed to 
draw definite conclusions concerning how substances affecting the dopaminergic, 
serotonergic and adrenergic systems could ameliorate or exacerbate bruxism in 
humans. The awareness of patients, psychiatrists, dentists, general practitioners and 
nurses that many psychotropic drugs cause side-effects related to oral health could 
improve remarkably the early detection and patient management. Extra precautions 
are needed, especially for patients with more than one co-morbid mental health 
issues with the possibilities of poly-pharmacy including combinations of antipsychotic 
and antidepressants. Furthermore, precautions must also be taken when performing 
surgery or prescribing analgesics, antibiotics or sedative agents due to adverse 
interaction with psychiatric medications. BMS treatment is not necessary in some 
cases; however, if severe, options include dental approaches such as oral 
appliances to reduce tooth damage and relieve jaw pain, psychological therapies 
such as cognitive behavioral therapy and pharmacological treatment including 
switching the psychotropic medications to an alternative with lower risk of Bruxism. 
 
Declaration of Interest: None 
Key points 
 Several clinical studies showed higher incidence of bruxism among 
psychiatric patients especially those suffering from schizophrenia.  
 Bruxism could result from peripheral morphological alterations such as 
malocclusion or multifactorial aetiology including a centrally mediated 
condition, modulated by drugs acting on CNS neurotransmitters.  
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 Psychostimulants may seriously damage the oral environment and cause 
bruxism by deregulating the DA mesocortical pathway.  
 BMS management include dental approaches such as oral appliances, 
psychological therapies and switching the psychotropic medications to an 
alternative with lower risk of Bruxism. 
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Table 1: Antipsychotic Drugs and their associated dental problems (Adapted from 
eMC and Reports/VigiAccess) 
 
Dental Oral Condition Antipsychotic medications associated with dental oral 
condition 
Bruxism Haloperidol, Aripiprazole, Perphenazine, Prochlorperazine, 
Olanzapine, Paliperidone, Risperidone, Quetiapine  
Dry mouth Haloperidol (common), Aripiprazole, Perphenazine, 
Prochlorperazine, Olanzapine (common), Paliperidone, 
Risperidone (common), Quetiapine (very common), 
Chlorpromazine (very common), Fluphenazine, Pericyazine, 
Trifluoperazine, Zuclopenthixol, Amisulpride (common) , 
Clozapine (common), Lurasidone (common), Promazine and 
Levopromazine (very Common) 
Hypersalivation Aripiprazole, Sulpiride, Zuclopenthixol, Amisulpride (very 
Common), Clozapine (very common), Lurasidone (common) 
orofacial dyskinesia Perphenazine 
 
*Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 







Figure 1: the number of reports showing antipsychotics medications associated with 
mastication disorders (Uppsala monitoring VigiAccess, search conducted 8.2.17)  
 
 
 
 
 
 
 
 
